Skip to main content

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Search

1062 result(s) found, displaying 451 to 475
  • Australian Public Assessment Report for Migalastat
  • Australian Public Assessment Report for Rituximab
  • Australian Public Assessment Report for Carbetocin
  • Australian Public Assessment Report for Ocrelizumab
  • Australian Public Assessment Report for Nivolumab
  • Australian Public Assessment Report for Pembrolizumab (rch)
  • Australian Public Assessment Report for Sarilumab (rch)
  • Australian Public Assessment Report for Bosentan
  • Australian Public Assessment Report for Sebelipase alfa
  • Australian Public Assessment Report for Adalimumab
  • Australian Public Assessment Report for Cladribine
  • Australian Public Assessment Report for Dupilumab
  • Australian Public Assessment Report for Suvorexant
  • Australian Public Assessment Report for Pembrolizumab [Keytruda]
  • Australian Public Assessment Report for insulin degludec (rys)
  • Australian Public Assessment Report for Eluxadoline [Viberzi] (for irritable bowel syndrome with diarrhoea)
  • Australian Public Assessment Report for Trifluridine/tipiracil [Lonsurf and Orcantas]

Help us improve the Therapeutic Goods Administration site